BidaskClub upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a buy rating to a strong-buy rating in a report published on Tuesday morning.
Other research analysts have also recently issued research reports about the stock. ValuEngine upgraded shares of Atara Biotherapeutics from a sell rating to a hold rating in a research note on Friday, February 2nd. Canaccord Genuity reiterated a buy rating and set a $70.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, May 8th. Guggenheim assumed coverage on shares of Atara Biotherapeutics in a research note on Thursday, March 15th. They set a neutral rating on the stock. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a hold rating to a buy rating and set a $45.00 price target on the stock in a research note on Tuesday, May 1st. Finally, Citigroup cut shares of Atara Biotherapeutics from a neutral rating to a sell rating in a research note on Thursday, February 15th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $42.50.
Shares of Atara Biotherapeutics stock opened at $50.40 on Tuesday. The firm has a market cap of $2.20 billion, a PE ratio of -12.60 and a beta of 2.55. Atara Biotherapeutics has a 1-year low of $11.80 and a 1-year high of $54.45.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.13). equities research analysts forecast that Atara Biotherapeutics will post -4.06 earnings per share for the current fiscal year.
In related news, CEO Isaac E. Ciechanover sold 8,800 shares of Atara Biotherapeutics stock in a transaction on Tuesday, May 22nd. The shares were sold at an average price of $51.74, for a total transaction of $455,312.00. Following the transaction, the chief executive officer now owns 812,613 shares in the company, valued at approximately $42,044,596.62. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Mitchall G. Clark sold 25,860 shares of Atara Biotherapeutics stock in a transaction on Friday, May 18th. The shares were sold at an average price of $50.03, for a total transaction of $1,293,775.80. Following the transaction, the executive vice president now owns 107,972 shares in the company, valued at approximately $5,401,839.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 170,471 shares of company stock worth $7,469,812. 10.60% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ATRA. Riverhead Capital Management LLC purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at $100,000. SG Americas Securities LLC purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at $107,000. Principal Financial Group Inc. purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at $214,000. MetLife Investment Advisors LLC purchased a new stake in Atara Biotherapeutics in the 4th quarter worth $217,000. Finally, Teacher Retirement System of Texas purchased a new stake in Atara Biotherapeutics in the 1st quarter worth $260,000.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.